SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Marcelo Vailati Negrao, Kathryn C. Arbour, Timothy F. Burns, Federico Cappuzzo, Anne-Marie C. Dingemans, Nicolas Girard, Bjorn Henning Gronberg, Maximilian Hochmair, Ticiana Leal, Colin R Lindsay, Shun Lu, Makoto Nishio, Luis G. Paz-Ares, Martin Reck, Joshua K. Sabari, Alexander I. Spira, William Nassib William, Aaron Chen, Carla M. Visseren Grul, Solange Peters
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Instituto Nazionale Tumori Regina Elena, Erasmus MC, Erasmus MC Cancer Institute, Université de Versailles Saint-Quentin-en-Yvelines, Institut Curie, Norwegian University of Science and Technology, St Olav's University Hospital, Winship Cancer Institute, The Christie Hospital, The Christie NHS Foundation Trust, Shanghai Chest Hospital, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, LungenClinic Grosshansdorf, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Virginia Cancer Specialists, Loxo Oncology at Lilly (United States), Eli Lilly (Netherlands), Centre Hospitalier Universitaire Vaudois, University of Lausanne
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4399570757